Stemline Therapeutics to Present at the 32nd Annual J.P. Morgan Healthcare Conference

        Print
| Source: Stemline Therapeutics, Inc.

NEW YORK, Jan. 7, 2014 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML) announced today that Ivan Bergstein, M.D., Stemline's CEO, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2014 at 11:00 AM PT. The conference will be held at the Westin St. Francis Hotel in San Francisco on January 13-16, 2014. A live webcast of the event can be viewed on the Company's website at www.stemline.com

About Stemline Therapeutics

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel oncology therapeutics that target both cancer stem cells (CSCs) as well as the tumor bulk. Stemline's clinical candidates, SL-401 and SL-701, have demonstrated clinical activity, including durable complete responses (CRs), in Phase 1/2 studies of patients with advanced hematologic and brain cancer, respectively. SL-401 is being advanced into pivotal programs in blastic plasmacytoid dendritic cell neoplasm (BPDCN) and third-line acute myeloid leukemia (AML) as well as other clinical studies in additional hematologic cancers. SL-701 is being advanced into later stage trials of adults with second-line glioblastoma multiforme (GBM) and children with brainstem and non-brainstem glioma. For more information about Stemline Therapeutics, visit www.stemline.com.

Forward-Looking Statements

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The factors that could cause our actual results to differ materially are identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

Mark Jacobson
Director, Corporate Development
Stemline Therapeutics, Inc.
750 Lexington Avenue
Eleventh Floor
New York, NY 10022
Tel: 646-502-2307
Email: